1. T-Cell Clonality; T cell antigen receptors, Gene Rearrangement; Laboratory

2. Here we review the conceptual foundations of T cell Clonality assays, including T cell ontogeny and T cell receptor …

3. Here we review the conceptual foundations of T cell Clonality assays, including T cell ontogeny and T cell receptor structure and function; we also provide an introduction to T cell receptor genomics and the concept of the T cell clonotype.

4. Thymic stromal cell cultures for t-cell differentiation

5. We conclude that skeletal muscle Antagonizes T cell exhaustion by protecting T cell proliferative potential from inflammation and replenishing the effector T cell progeny pool in lymphoid organs.

6. CD4+ T-cell absolute counts was 1.5 times higher than the percent C.V. for CD4+ T-cell percentages.

7. B-cell Prolymphocytic Leukemia (T-PLL) is a mature post-thymic T-cell malignancy with aggressive clinical course.

8. The AVN composed of four types cells, P cell, T cell, Purkinje cell and normal cardiac working cell.

9. Cell mediated Immune Response: Cell mediated immune response is carried out by the T-cells or T lymphocytes (Fig

10. Chimeric Antigen Receptor (CAR) T-cell Therapy

11. T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive haematologic cancer associated with a high white blood cell count.

12. We propose that the TCF1-Bcl6 axis Counteracts type I interferon to repress T cell exhaustion and maintain T cell stemness, which is critical for persistent antiviral CD8 T cell responses in chronic infection.

13. T lymphocyte, endothelial cell, matrix metalloproteinase, inflammation, transendothelial migration, integrins, cell adhesion molecules.

14. Adoptive T-cell therapies with T-cells modified with chimeric antigen receptors (CAR-T) also causes CRS.

15. The APC then travels to a lymph node, where it presents the displayed allergen to a CD4+ T-cell, or T-helper cell.

16. T cell Clonality testing has important clinical and research value, providing a specific and reproducible assessment of clonal diversity in T cell proliferations

17. T cell Clonality testing has important clinical and research value, providing a specific and reproducible assessment of clonal diversity in T cell proliferations

18. Costimulatory molecules are key elements in T cell activation.

19. Cutaneous T-cell lymphoma is a type of cancer

20. Drug containing antibodies for treatment of t cell specific immune reactions and t cells leukemias

21. Such Bulged pMHC-I complexes represent challenges for T-cell receptor (TCR) ligation, although t …

22. CD8+ (Cytotoxic) T cells, like CD4+ Helper T cells, are generated in the thymus and express the T-cell receptor

23. T cell Clonality testing has important clinical and research value

24. Upon contact with its specific antigen, the T cell receptor transduces an activation signal into the T cell, leading to proliferation, cytokine production, or efficient cytotoxicity.

25. Clinical and experimental data suggest impairment of T-cell functions.

26. Novel peptide for inhibiting t cell activity and use thereof

27. Cutaneous T-cell lymphoma (CTCL) is a general term for several types of T-cell lymphomas of the skin, including mycosis fungoides, Sézary syndrome, primary Cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, granulomatous slack skin disease, pagetoid reticulosis, and subCutaneous panniculitis-like T-cell lymphoma, to name a few.

28. A Cytotoxic T cell releases toxic substances that kill infected cells.

29. Normalization of defective t cell responsiveness through manipulation of thymic regeneration

30. Immunocytologic studies revealed the T-cell origin of these thymic type lymphomas.

31. This allows killer T cells to recognize the tumor cell as abnormal.

32. An animal model and method of treatment for human t cell leukemia

33. Allo- and auto-reactive t-cell epitopes from rhesus protein and their use

34. As with B cells, each type of T cell recognizes a different antigen.

35. Antibiotic exposure Accelerates diabetes in NOD mice and alters CD4+ T-cell populations

36. T-cell kinetics, activation and cytokine production are highly sensitive to nasal steroids.

37. Cutaneous T-cell lymphomas (CTCL) are caused by the uncontrolled division of abnormal T-cells that have accumulated in the skin

38. SLE-LTEAI-FIRE Dual Path Communicator, Cell/IP, AT&T LTE ™, ABS

39. Similarly, cell-mediated immunity is active when the organisms’ T-cells are stimulated, and passive when T cells come from another organism.

40. These cells are characterized by high endocytic activity and low T-cell activation potential.

41. An Antigen-specific B cell antibody specifically recognizes a TI-2 Antigen, but without T cell help, a memory response is not seen.

42. A Th 1/T helper 2 imbalance characterizes T-cell responses in active drinkers with ARC, whereas IL-4 production prevails in Abstinents

43. The present invention relates to an anti-inflammatory, skin-regenerative, whitening, antioxidant, or wound-healing composition containing a culture medium of adipose-derived stem cell-T (ADSC-T) cells as an active ingredient, in which T-antigen is introduced into an adipose-derived stem cell.

44. As part of the standard T cell Clonality assay, most laboratories rely on the demonstration of electrophoretic migration patterns for the determination of Clonality: a prototypical ‘polyclonal’ T cell population will produce an electropherogram with a Gaussian distribution of low-fraction amplicon peaks; in contrast, a bona fide ‘monoclonal’ T cell population will produce an electropherogram with a …

45. Haematology See Plasminogen Activation Immunology See Complement Activation, Lymphocyte Activation, Macrophage Activation, T cell Activation

46. The delivery of the second signal by the antigen-presenting cell rescues the activated T cell from Anergy, allowing it to produce the lymphokines

47. (Merkel cell carcinoma, NCI Thesaurus) A drug used together with UV light to treat psoriasis, vitiligo, and skin nodules of Cutaneous T-cell lymphoma

48. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy

49. 24 Objective To study the relationship of Epstein Barr virus ( EBV ) and T cell lymphoma.

50. Amoeboid T-cell migration, physical cell-fiber interaction, and contact guidance within 3D collagen matrix in the absence or presence of protease inhibitor cocktail

51. Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases

52. Models of T cell Anergy affecting both CD4(+) and CD8(+) cells fall into two broad cate …

53. Adaptive immune responses to AAV Capsid usually result in neutralizing antibody responses and T-cell responses

54. Glycolysis and glutaminolysis Cooperatively control T cell function by limiting metabolite supply to N-glycosylation Elife

55. The company is involved in developing a pipeline of multiple Allogeneic T cell product candidates utilizing

56. I discovered a specific type of immune cell, the helper T cell, was present inside that material that I implanted and absolutely critical for wound healing.

57. This page includes the following topics and synonyms: Cell-Mediated Immunodeficiency, Cell mediated Immunity Disorder, T-Cell Disorder, Severe Combined Immunodeficiency, SCID, Ataxia Telangiectasia, Wiscott-Aldrich Syndrome, DiGeorge Syndrome, Velocardiofacial Syndrome, Congenital Thymic Aplasia.

58. About 76% of T-cell neoplasms are reported to express CD5, and it is also found in chronic lymphocytic leukemia and mantle cell lymphoma (both being B cell malignancies), that do not express CD3.

59. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T-cell (CAR T

60. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T

61. In 2010 Clapton started appearing as a spokesman for T-Mobile, advertising their MyTouch Fender cell phone.

62. Here, we review the functional abnormalities and the contribution of different T-cell subsets to rheumatoid inflammation.

63. The T-cell stimulator will slow down the rate of change but until I find the cause...

64. The Clonality and T‐cell fraction were log2 transformed to correct for the skewness of the data

65. Achilles pipeline Our lead product is a personalised tumour-derived T cell therapy targeting clonal cancer neoantigens

66. Neuroinvasive West Nile Infection Elicits Elevated and Atypically Polarized T Cell Responses That Promote a Pathogenic Outcome.

67. Preventives or remedies for sensitized t cell-related diseases containing il-6 antagonists as the active ingredient

68. Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases

69. Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors

70. The Arnt-STAT3 axis is a critical regulator of TCRalphabeta CD8alphaalpha intestinal intraepithelial T-cell development and differentiation.

71. Clonal expansion was analyzed by quantifying similar T cell clones on the basis of the TCR sequence information

72. Establishment of a GAT-specific suppressor T cell clone from GAT-tolerant responders which Afferently regulates DTH responses

73. The invention provides a method for modulating CD4 T cell function by administration of antibodies to CD-40.

74. Absorption of anti-brain serum with liver and plasmocytoma cells led to residual specific anti T-cell activity.

75. The relationship between acral ischemia and T-cell-lymphoma is not clear but is discussed in this article.

76. Leadership team: Cabaletta Bio has brought together leading scientists and experts in cell therapy and autoimmune disease to develop CAAR T cell therapies that offer a potential one-time cure of B cell-mediated autoimmune diseases.

77. This displaces the antigenic peptide away from the TCR and circumvents the normal mechanism for T-cell activation.

78. The corrosion behavior of 7075 T 6 aluminuium alloy in EXCO solution was studied by occluded cell method.

79. Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell

80. B cells are involved in the humoral immune response, whereas T cells are involved in cell-mediated immune response.